VEGFA and macular retinal edema: IV injection of anti-VEGF agents (ranibizumab, Lucentis, Genentech, Inc., South San Francisco, CA, USA) did not affect the incidence of collateral vessel formation on the disc or in the retina in patients in the BRAVO or Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein OcclUsIon Study: Evaluation of Efficacy and Safety (CRUISE) studies [95].